Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Shares of CureVac are trading higher by 15% during Monday's session. The stock is gaining following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.

CureVac (NASDAQ:CVAC) was able to report positive data from Part A of its phase 1 study using its vaccine candidate CVGBM for the treatment of patients with HLA-*02:01-positive patients with newly ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its first death from the virus.

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through North America.

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

CureVac (NASDAQ:CVAC – Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 3,940,000 shares ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer, BioNTech win bid to invalidate CureVac's UK COVID ...

CureVac Price Performance Shares of NASDAQ:CVAC opened at $2.87 on Monday. The stock has a market cap of $642.54 million, a price-to-earnings ratio of 5.22, a PEG ratio of 0.24 and a beta of 2.59 ...

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses. Get Wall ...